Literature DB >> 10926293

A human epithelium-specific vector optimized in rat pneumocytes for lung gene therapy.

D R Koehler1, Y H Chow, J Plumb, Y Wen, B Rafii, R Belcastro, M Haardt, G L Lukacs, M Post, A K Tanswell, J Hu.   

Abstract

Gene therapy vectors based on mammalian promoters offer the potential for increased cell specificity and may be less susceptible than viral promoters to transcription attenuation by host cytokines. The human cytokeratin 18 (K18) gene is naturally expressed in the lung epithelia, a target site for gene therapies to treat certain genetic pediatric lung diseases. Our original vector based on the promoter and 5' control elements of K18 offered excellent epithelial cell specificity but relatively low expression levels compared with viral promoters. In the present study, we found that adding a stronger SV40 poly(A) signal boosted primary rat lung epithelial cell expression but greatly reduced cell specificity. Addition of a 3' portion of the K18 gene to our vector as a 3' untranslated region (UTR) improved epithelial cell-specific expression by reducing expression in lung fibroblasts. The effect of the 3' UTR was not related to gross differences in cell-specific splicing. A deletion variant of this UTR further increased lung epithelial cell expression while retaining some cell specificity. These data illustrate the possibilities for using 3' UTR to regulate cell-specific transgene expression. Our improved K18 vector should prove useful for pediatric lung gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926293     DOI: 10.1203/00006450-200008000-00011

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus.

Authors:  Paul B McCray; Lecia Pewe; Christine Wohlford-Lenane; Melissa Hickey; Lori Manzel; Lei Shi; Jason Netland; Hong Peng Jia; Carmen Halabi; Curt D Sigmund; David K Meyerholz; Patricia Kirby; Dwight C Look; Stanley Perlman
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

2.  Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia.

Authors:  David R Koehler; Umadevi Sajjan; Yu-Hua Chow; Bernard Martin; Geraldine Kent; A Keith Tanswell; Colin McKerlie; Janet F Forstner; Jim Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

3.  GFP-tagged CFTR transgene is functional in the G551D cystic fibrosis mouse colon.

Authors:  D Oceandy; B McMorran; R Schreiber; B J Wainwright; K Kunzelmann
Journal:  J Membr Biol       Date:  2003-04-01       Impact factor: 1.843

Review 4.  Clinical review: gene-based therapies for ALI/ARDS: where are we now?

Authors:  James Devaney; Maya Contreras; John G Laffey
Journal:  Crit Care       Date:  2011-06-20       Impact factor: 9.097

5.  A complementation method for functional analysis of mammalian genes.

Authors:  Juana Maria Gonzalez-Santos; Huibi Cao; Anan Wang; David R Koehler; Bernard Martin; Roya Navab; Jim Hu
Journal:  Nucleic Acids Res       Date:  2005-06-08       Impact factor: 16.971

6.  Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Authors:  Min-Wen Ku; Pierre Authié; Maryline Bourgine; François Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Ingrid Fert; Sébastien Chardenoux; Llta Lafosse; Delphine Cussigh; David Hardy; Kirill Nemirov; Françoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau
Journal:  EMBO Mol Med       Date:  2021-10-25       Impact factor: 12.137

7.  TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy.

Authors:  Emily Xia; Yiqian Zhang; Huibi Cao; Jun Li; Rongqi Duan; Jim Hu
Journal:  Genes (Basel)       Date:  2019-01-11       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.